FDA PCAC July 2026: 29 Days Out What Researchers Need to Know Before the Hearing The FDA Pharmacy Compounding Advisory Committee convenes July 2324, 2026 to rule on 503A status for BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon
Managing side effects like nausea from Tirzepatide often requires guidance from experts and small changes in daily habits
This control has enabled consistent growth in the GLP-1 receptor agonist segment
severe or persistent abdominal pain should be assessed promptly Thyroid C-cell tumours observed in rodent studies with GLP-1 receptor agonists
Can I switch from tirzepatide to retatrutide directly, or do I need to taper off first
Key takeaways Alcohol and coffee are the most-discussed drinks on GLP-1 subreddits